Janiczek Wealth Management LLC Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Janiczek Wealth Management LLC bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 1,213 shares of the company’s stock, valued at approximately $97,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Washington Trust Advisors Inc. acquired a new position in Axsome Therapeutics during the 4th quarter worth about $26,000. SG Americas Securities LLC bought a new stake in Axsome Therapeutics in the fourth quarter valued at about $170,000. Neo Ivy Capital Management bought a new stake in Axsome Therapeutics in the third quarter valued at about $204,000. DAVENPORT & Co LLC acquired a new position in Axsome Therapeutics in the fourth quarter valued at about $304,000. Finally, Aigen Investment Management LP bought a new position in Axsome Therapeutics during the fourth quarter worth about $308,000. 81.49% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on AXSM shares. Truist Financial reissued a “buy” rating and set a $150.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday, March 26th. Morgan Stanley raised Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $90.00 to $115.00 in a research note on Monday, April 29th. Mizuho reaffirmed a “buy” rating and set a $106.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, June 12th. Citigroup cut their price target on shares of Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, May 7th. Finally, Royal Bank of Canada increased their price objective on shares of Axsome Therapeutics from $127.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $122.08.

Insider Buying and Selling

In other news, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Mark L. Jacobson sold 7,910 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $74.31, for a total transaction of $587,792.10. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $429,734.73. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Mark L. Jacobson sold 24,662 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,821 shares of company stock valued at $2,887,462. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of AXSM stock traded up $2.32 on Thursday, reaching $79.44. The stock had a trading volume of 306,977 shares, compared to its average volume of 712,744. Axsome Therapeutics, Inc. has a 12 month low of $55.02 and a 12 month high of $98.40. The firm’s 50-day moving average is $74.45 and its two-hundred day moving average is $78.59. The company has a quick ratio of 3.09, a current ratio of 3.20 and a debt-to-equity ratio of 1.25.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 6th. The company reported ($1.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.11. Axsome Therapeutics had a negative return on equity of 87.17% and a negative net margin of 118.07%. The business had revenue of $75.00 million for the quarter, compared to analyst estimates of $69.91 million. On average, equities research analysts predict that Axsome Therapeutics, Inc. will post -4.7 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.